ERBB2 and non-small cell lung carcinoma: In cohort B of a phase II trial, 11 pretreated patients with HER2 MUT NSCLC treated with this drug reported an ORR of 22% and a DCR of 66%; regarding safety, the most common AEs were prolonged QTc (corrected QT interval) at 60.9% (G ≥ 3 34.8%), skin rash at 43.5% (G ≥ 3 4.3%), and diarrhoea at 21.7% G ≥ 3 4.3%) [70].